亚太药业11月11日获融资买入8380.95万元，融资余额2.91亿元

Core Insights - On November 11, Asia-Pacific Pharmaceutical Co., Ltd. saw a stock increase of 1.68% with a trading volume of 1.127 billion yuan [1] - The company reported a financing buy-in amount of 83.81 million yuan and a net financing buy of 1.10 million yuan on the same day [1][2] - As of November 11, the total financing and securities lending balance for the company was 291 million yuan, which is 4.61% of its market capitalization [1] Financing Summary - The financing buy-in for Asia-Pacific Pharmaceutical on November 11 was 83.81 million yuan, with a current financing balance of 291 million yuan, indicating a high level compared to the past year [1] - The financing balance exceeds the 90th percentile level over the past year, indicating a strong position in the market [1] Securities Lending Summary - On November 11, there were no shares repaid or sold in the securities lending market, with a total lending balance of 0.00 yuan, also indicating a high level compared to the past year [1] Company Overview - Asia-Pacific Pharmaceutical Co., Ltd. was established on December 31, 2001, and listed on March 16, 2010 [1] - The company specializes in pharmaceutical manufacturing, including the research, production, and sales of chemical preparations and raw materials [1] - The revenue composition includes 56.49% from antibiotic preparations, 42.84% from non-antibiotic preparations, and 0.67% from other sources [1] Financial Performance - As of September 30, the number of shareholders increased to 91,500, a rise of 66% compared to the previous period [2] - The average number of circulating shares per person decreased by 39.76% to 8,152 shares [2] - For the period from January to September 2025, the company reported a revenue of 22.8 million yuan, a decrease of 25.59% year-on-year, while the net profit attributable to the parent company was 97.20 million yuan, a significant increase of 2909.49% [2] Dividend Information - Since its A-share listing, Asia-Pacific Pharmaceutical has distributed a total of 186 million yuan in dividends, with no dividends paid in the last three years [3]